Eli Lilly plans to create 3,000 jobs for skilled workers by building four new pharmaceutical manufacturing sites in the US. This expansion is part of a $50 billion investment since 2020. Three of the sites will focus on producing key ingredients for medicines, strengthening Lilly’s supply chain by bringing some manufacturing back to the US. The fourth site will support the production of injectable treatments.
The construction of these sites will provide around 10,000 jobs, and once operational, they will employ skilled professionals like operations staff, scientists, lab technicians, and engineers. These new facilities will boost local economies by increasing spending, diversifying the economy, improving infrastructure, generating tax revenue, and offering training and development opportunities.
Edgardo Hernandez, Lilly’s manufacturing operations president, highlighted the importance of investing in advanced manufacturing to ensure the production of safe and reliable medicines, pushing American innovation to lead the world in pharmaceuticals.
From 2020 to 2024, Lilly committed $23 billion to expanding its presence in the US. This includes investments in areas like North Carolina’s Research Triangle Park and Concord, updates to facilities in Indianapolis, projects in Lebanon, Indiana, and expanding a site in Kenosha County, Wisconsin. In August 2024, Lilly also opened a research and development hub in Boston’s Seaport district.